Resverlogix Appoints Bradley Glass to Board of Directors
Resverlogix (RVXCF) announced on November 18, 2025 the appointment of Bradley Glass, J.D. to its board of directors.
Mr. Glass joins the board with four years as General Counsel at Hepalink USA, where he managed U.S. legal matters, and over 20 years in private law practice representing clients in federal, state and local courts and administrative tribunals. He holds degrees from Wabash College and Indiana University School of Law.
The company's chairman and CEO said Glass will add legal and business experience to the board, and Glass said he looks forward to supporting Resverlogix and the development of apabetalone.
Resverlogix (RVXCF) ha annunciato il 18 novembre 2025 l nomina di Bradley Glass, J.D. nel consiglio di amministrazione.
Il signor Glass entra nel consiglio con quattro anni di esperienza come General Counsel presso Hepalink USA, dove ha gestito questioni legali statunitensi, e oltre 20 anni di attività legale privata rappresentando clienti nei tribunali federali, statali e locali e in tribunali amministrativi. Possiede lauree dalla Wabash College e dalla Indiana University School of Law.
Il presidente e amministratore delegato dell'azienda ha detto che Glass apporterà esperienza legale e aziendale al consiglio, e Glass ha dichiarato di essere lieto di sostenere Resverlogix e lo sviluppo di apabetalone.
Resverlogix (RVXCF) anunció el 18 de noviembre de 2025 la designación de Bradley Glass, J.D. para su junta directiva.
El Sr. Glass se incorpora a la junta con cuatro años como Asesor General en Hepalink USA, donde gestionó asuntos legales estadounidenses, y más de 20 años en la práctica privada de la abogacía representando a clientes ante tribunales federales, estatales y locales y tribunales administrativos. Posee títulos de Wabash College y de la Indiana University School of Law.
El presidente y director ejecutivo de la empresa dijo que Glass aportará experiencia legal y empresarial a la junta, y Glass afirmó que espera apoyar a Resverlogix y el desarrollo de apabetalona.
Resverlogix (RVXCF)가 2025년 11월 18일에 Bradley Glass, J.D.를 이사회에 임명했다고 발표했습니다.
Glass 씨는 Hepalink USA에서 일반 법무 담당 이사로 4년간 재직하며 미국 내 법무 문제를 관리했고, 20년이 넘는 시간 동안 연방, 주 및 지방 법원 및 행정 재판소에서 고객을 대리하는 민간 법률 활동에 종사해 왔습니다. 그는 Wabash College와 Indiana University School of Law에서 학위를 받았습니다.
회장 겸 최고경영자는 Glass가 이사회에 법률 및 비즈니스 경험을 더할 것이며, Glass는 Resverlogix와 아페타볼론의 개발을 돕게 되기를 기대한다고 말했습니다.
Resverlogix (RVXCF) a annoncé le 18 novembre 2025 la nomination de Bradley Glass, J.D. au conseil d'administration.
M. Glass rejoint le conseil avec quatre ans en tant que conseiller général chez Hepalink USA, où il gérait les questions juridiques américaines, et plus de 20 ans dans la pratique privée du droit représentant des clients devant les tribunaux fédéraux, étatiques et locaux et des tribunaux administratifs. Il est diplômé du Wabash College et de la Indiana University School of Law.
Le président et directeur général de l'entreprise a déclaré que Glass apportera une expérience juridique et commerciale au conseil, et Glass a déclaré qu'il se réjouit de soutenir Resverlogix et le développement de l'apabetalone.
Resverlogix (RVXCF) gab am 18. November 2025 die Berufung von Bradley Glass, J.D. in den Vorstand bekannt.
Herr Glass tritt dem Vorstand mit vier Jahren als General Counsel bei Hepalink USA bei, wo er US-Rechtsangelegenheiten leitete, und mit über 20 Jahren in der privaten Rechtsberatung, in der er Mandanten vor Bundes-, Landes- und lokalen Gerichten sowie vor Verwaltungsgremien vertreten hat. Er besitzt Abschlüsse vom Wabash College und der Indiana University School of Law.
Der Vorsitzende und CEO des Unternehmens sagte, Glass werde dem Vorstand rechtliche und geschäftliche Erfahrungen hinzufügen, und Glass sagte, er freue sich darauf, Resverlogix und die Entwicklung von apabetalone zu unterstützen.
Resverlogix (RVXCF) أعلنت في 18 نوفمبر 2025 عن تعيين Bradley Glass, J.D. في مجلس إدارة الشركة.
ينضم السيد Glass إلى المجلس وهو يملك أربع سنوات من الخبرة كـ General Counsel في Hepalink USA، حيث أدار قضايا قانونية أميركية، وأكثر من 20 عاماً في الممارسة القانونية الخاصة ممثلاً العملاء أمام المحاكم الفيدرالية والولائية والمحاكم المحلية والهيئات الإدارية. ويحمل شهادات من كلية وابيش وجامعة إنديانا كلية القانون.
قال رئيس مجلس الإدارة والمدير التنفيذي للشركة إنه سيضيف Glass خبرة قانونية وتجارية إلى المجلس، وقال Glass إنه يتطلع إلى دعم Resverlogix وتطوير الدواء apabetalone.
- None.
- None.
Calgary, Alberta--(Newsfile Corp. - November 18, 2025) - Resverlogix Corp. (TSX: RVX) ("Resverlogix", or the "Company") today announces the appointment of Mr. Bradley Glass, J.D. as a member of the Company's board of directors.
Mr. Glass has served as the General Counsel of Hepalink USA, Inc. and its subsidiaries ("Hepalink") for the past four years. In that role, Mr. Glass is responsible for managing all of Hepalink's U.S. legal issues. Prior to joining Hepalink, Mr. Glass was in private law practice for over twenty years and advised, counseled, and represented clients all over the United States on a broad range of matters. Mr. Glass has represented and litigated numerous matters in federal, state, and local courts and administrative tribunals on a wide range of complex business and regulatory matters. Mr. Glass is a graduate of Wabash College and the Indiana University School of Law.
"We are very pleased to welcome Bradley Glass to Resverlogix's board of directors," said Donald McCaffrey, Chairman and CEO. "Bradley's decades of legal and business experience will bring a valuable perspective to our Board. We look forward to Bradley's insights and contributions in advancing our strategic objectives."
"I'm thrilled to join the board and look forward to supporting Resverlogix's progress," said Mr. Glass. "This appointment reflects Resverlogix and Hepalink's common goal of apabetalone's successful development."
About Resverlogix
Founded in 2001, Resverlogix is a Calgary based late-stage biotechnology company, and a world leader in epigenetics, with the goal of developing first-in-class therapies for the benefit of patients with chronic disease.
Resverlogix is developing a new class of epigenetic therapies designed to regulate the expression of disease-causing genes. We aim to improve patients' lives by restoring biological functions – altered by serious illnesses such as cardiovascular disease – back to a healthier state.
The Company's clinical program is focused on evaluating the lead epigenetic candidate apabetalone for the treatment of cardiovascular disease, associated comorbidities, and post COVID-19 conditions.
Resverlogix has partnered with EVERSANA™, the pioneer of next generation commercial services to the global life sciences industry, to support the rapid commercialization of apabetalone for cardiovascular disease, post COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.
Resverlogix common shares trade on the Toronto Stock Exchange (TSX: RVX).
Follow us on:
- Twitter: @Resverlogix_RVX
- LinkedIn: https://www.linkedin.com/company/resverlogix-corp-/
Forward-Looking Statements:
This news release may contain certain forward-looking information as defined under applicable Canadian securities legislation, that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts", and other similar expressions. In particular, this news release includes forward-looking information related to the potential role of apabetalone in the treatment of patients with cardiovascular disease, post COVID-19 conditions, pulmonary arterial hypertension, associated comorbidities, and other chronic diseases. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous assumptions and risk factors including those discussed in our Annual Information Form and most recent MD&A which are incorporated herein by reference and are available through SEDAR at www.sedarplus.ca. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement and are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
For further information please contact:
Investor Relations
Email: ir@resverlogix.com
Phone: 403-254-9252
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/275066
FAQ
Who is Bradley Glass and when was he appointed to the Resverlogix board (RVXCF)?
What is Bradley Glass's professional background relevant to Resverlogix (RVXCF)?
What qualifications does Bradley Glass have for a board role at Resverlogix (RVXCF)?
Did Resverlogix management comment on the board appointment for RVXCF?
Will Bradley Glass have a role in Resverlogix's apabetalone program (RVXCF)?
Where can investors find Bradley Glass's prior experience noted in the appointment for RVXCF?
